---
schema_version: "secwatch.filing_event.v1"
accession: "0001396814-22-000066"
form_type: "8-K"
ticker: "PCRX"
cik: "0001396814"
company_name: "Pacira BioSciences, Inc."
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T08:35:11.275729+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Pacira Q3 revenue up 31% to $167.5M, GAAP net loss $0.7M; EXPAREL sales $132.6M, patent to 2041

## Summary
- Total revenues $167.5M (+31% YoY); EXPAREL $132.6M (+9%), ZILRETTA $26.5M.
- GAAP net loss $0.7M ($0.02 loss/share) vs prior-year net income $17.7M ($0.40).
- Non-GAAP net income $29.9M ($0.65/share); adjusted EBITDA $55.2M vs $48.1M.
- New EXPAREL composition patent (No. 11,452,691) expires Jan 2041; positive Phase 3 lower extremity nerve block results.
- CHMP positive opinion for pediatric EXPAREL use; encouraging Phase 1 data for PCRX-201 gene therapy.

## SEC filing metadata
- accession: 0001396814-22-000066
- form_type: 8-K
- ticker: PCRX
- cik: 0001396814
- company_name: Pacira BioSciences, Inc.
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1396814/000139681422000066/0001396814-22-000066-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1396814/000139681422000066/pcrx-20221103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001396814-22-000066
- JSON: https://secwatch.observer/filing/0001396814-22-000066.json
- Plain text: https://secwatch.observer/filing/0001396814-22-000066.txt

## Key facts
- Earnings Releases
  Pacira BioSciences, Inc. reported the third quarter ended September 30, 2022 results: revenue $167.5 million, net income $0.7 million, or $(0.02) per share (basic and diluted), EPS $(0.02) per share (basic and diluted).
  - Period: the third quarter ended September 30, 2022
  - Revenue: $167.5 million
  - Net income: $0.7 million, or $(0.02) per share (basic and diluted)
  - EPS: $(0.02) per share (basic and diluted)
  - Result: reported results
  source text: in such a filing. --- EX-99.1 (EX-99.1) --- FOR IMMEDIATE RELEASE NEWS RELEASE Pacira BioSciences Reports Third Quarter 2022 Financial Results -- Third quarter revenue of $167 million, increased 31% over prior year -- -- Conference call today at 8:30 a.m. ET -- TAMPA, FL, November 3, 2022 - Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its
  evidence_url: https://www.sec.gov/Archives/edgar/data/1396814/000139681422000066/0001396814-22-000066-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.